Selecta Biosciences Inc

NASDAQ:SELB   12:59:58 PM EDT
2.90
-0.28 (-8.80%)
Products, Regulatory

Selecta Biosciences Provides Update On Phase 1/2 Clinical Trial Of Sel-302 For The Treatment Of Methylmalonic Acidemia

Published: 11/24/2021 22:01 GMT
Selecta Biosciences Inc (SELB) - Selecta Biosciences Provides Update on Phase 1/2 Clinical Trial of Sel-302 for the Treatment of Methylmalonic Acidemia.
Selecta Biosciences Inc - U.S. FDA Placed a Clinical Hold on Phase 1/2 Clinical Trial of Sel-302 for Treatment of Patients With Methylmalonic Acidemia.
Selecta Biosciences Inc - There Were No Outstanding Clinical Or Pre-clinical Questions in FDA Letter.
Selecta Biosciences - FDA Issued Clinical Hold to Obtain Additional Info on Chemistry, Manufacturing, Controls Related to Mma-101 Product Candidate.
Selecta Biosciences Inc - No Human Patients Will Be Dosed With Mma-101 Until All of FDA's Questions Are Resolved.